Rezdiffra (Resmetirom) Patent Expiration, LOE Window & CMS Spending

Rezdiffra (Resmetirom) by Madrigal: FDA Orange Book core substance LOE 2033-09-17 (last listed 2045-02-04), 0 AB generics, $87.8M 2024 CMS Part D & Medicaid spend, and $3,950 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMadrigal
FDA Application & PathwayN217785 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2033-09-17
Last Listed Patent or Exclusivity Date2045-02-04
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$87.8M
2024 Medicare Part D Spend$69.1M
2024 Medicaid Spend$18.7M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($3,950 intro WAC)